Intensity Therapeutics, Inc. Common stock (INTS)vsBeiGene, Ltd. (ONC)
INTS
Intensity Therapeutics, Inc. Common stock
$5.92
-4.82%
HEALTHCARE · Cap: $15.15M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
INTS
Avoid21
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INTS.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : INTS
The strongest argument for INTS centers on Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : INTS
The primary concerns for INTS are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
INTS profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
INTS carries more volatility with a beta of 4.28 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 21/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Intensity Therapeutics, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
Intensity Therapeutics, Inc. is a forward-thinking biotechnology company focused on revolutionizing cancer treatment through its innovative drug delivery systems. By enhancing the efficacy of immuno-oncology therapies while minimizing systemic side effects, Intensity Therapeutics addresses critical unmet needs in the oncology landscape. With a robust foundation in cutting-edge research and a commitment to improving patient outcomes, the company is well-positioned to lead advancements in targeted therapies that effectively harness and amplify the body's immune response against cancer.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?